Perjeta is named as an intervention in 15 current clinical trials in our Germany, France, Spain, Italy, Portugal, Brazil, Israel, Mexico, China, Belgium, Poland, Canada, Japan, South Korea, Australia, UK, USA, Netherlands, Switzerland, Austria, Czechia, Taiwan, Denmark, Norway and Sweden registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Dana-Farber Cancer Institute (2). The most-studied condition is Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 7 |
| HER2-positive Breast Cancer | 3 |
| Breast Neoplasms | 2 |
| HER2 Positive Breast Cancer | 1 |
| Neoplasm Metastasis | 1 |
| Solid Tumors | 1 |
| Invasive Breast Cancer | 1 |
| HER-2 Positive Breast Cancer | 1 |
| Estrogen Receptor Positive Breast Cancer | 1 |
| Metastatic Breast Cancer With a Isolated Brain Progression | 1 |
| Heart Failure | 1 |
| Circulating Tumor Cell | 1 |
| Breast Diseases | 1 |
| Stage II Breast Cancer | 1 |
| Stage III Breast Cancer | 1 |
A trial with sites in more than one country appears in each of those registers.
15 current trials in our Germany, France, Spain, Italy, Portugal, Brazil, Israel, Mexico, China, Belgium, Poland, Canada, Japan, South Korea, Australia, UK, USA, Netherlands, Switzerland, Austria, Czechia, Taiwan, Denmark, Norway and Sweden registers name Perjeta as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 15 trials are recruiting: 2 with sites in Brazil, 1 with sites in Canada, 1 with sites in Netherlands and 1 with sites in Sweden. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Dana-Farber Cancer Institute (2), Seagen, a wholly owned subsidiary of Pfizer (1), Genentech, Inc (1) and Hoffmann-La Roche (1), among 14 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Perjeta works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Perjeta works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Perjeta (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.